Background: Bearing multidimensional tumor-relevant information ranging from genomic alterations to proteomic makeup, circulating tumor cells (CTCs) constitute a promising material for liquid biopsy. The clinical validity of CTCs has been most extensively studied in metastatic breast cancer (MBC). The Cellsearch assay is currently the most widely used, while alternative strategies are pursued. A filtration-based microfluidic device has been described for CTC enrichment, but its clinical relevance remains unknown. Methods: In this preliminary study, we prospectively enrolled 47 MBC patients and evaluated the performance of the abovementioned CTC assay for tumor burden monitoring and human epidermal growth factor receptor 2 (HER2) status determination. Results: At baseline, 51.1% patients (24/47) were CTC positive. CTC count and positivity were also significantly higher in samples that accompanied poorer radiographic response evaluations. Serial blood draws suggested that CTC count enabled more accurate monitoring of tumor burden than serum markers carcinoembryonic antigen and cancer antigen 15-3. Also, in contrast to previous reports, CTC-HER2 status was moderately consistent with tumor-HER2 status. CTC-HER2 status assessment was further supported by HER2 copy number measurements in select samples. Conclusion: The preliminary results from this study suggest promise for the interrogated CDC assay in several aspects, including sensitive CTC detection, accurate disease status reflection, and HER2 status determination. More studies are warranted to validate these findings and further characterize the value of CTC assay.

1.
Pantel
K
,
Speicher
MR
.
The biology of circulating tumor cells
.
Oncogene
.
2016 Mar 10
;
35
(
10
):
1216
24
.
2.
Cabel
L
,
Proudhon
C
,
Gortais
H
,
Loirat
D
,
Coussy
F
,
Pierga
JY
,
.
Circulating tumor cells: clinical validity and utility
.
Int J Clin Oncol
.
2017 Jun
;
22
(
3
):
421
30
.
3.
Cristofanilli
M
,
Budd
GT
,
Ellis
MJ
,
Stopeck
A
,
Matera
J
,
Miller
MC
,
.
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
.
N Engl J Med
.
2004 Aug 19
;
351
(
8
):
781
91
.
4.
Bidard
FC
,
Peeters
DJ
,
Fehm
T
,
Nolé
F
,
Gisbert-Criado
R
,
Mavroudis
D
,
.
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
.
Lancet Oncol
.
2014 Apr
;
15
(
4
):
406
14
.
5.
Rack
B
,
Schindlbeck
C
,
Jückstock
J
,
Andergassen
U
,
Hepp
P
,
Zwingers
T
,
.
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients
.
J Natl Cancer Inst
.
2014 May 15
;
106
(
5
):
dju066
.
6.
Janni
WJ
,
Rack
B
,
Terstappen
LW
,
Pierga
JY
,
Taran
FA
,
Fehm
T
,
.
Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer
.
Clin Cancer Res
.
2016 May 15
;
22
(
10
):
2583
93
.
7.
Vasseur
A
,
Kiavue
N
,
Bidard
FC
,
Pierga
JY
,
Cabel
L
.
Clinical utility of circulating tumor cells: an update
.
Mol Oncol
.
2021
;
15
(
6
):
1647
66
.
8.
Liu
Y
,
Liu
Q
,
Wang
T
,
Bian
L
,
Zhang
S
,
Hu
H
,
.
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
.
BMC Cancer
.
2013 Apr 23
;
13
:
202
.
9.
Zhang
S
,
Li
L
,
Wang
T
,
Bian
L
,
Hu
H
,
Xu
C
,
.
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
.
BMC Cancer
.
2016 Jul 25
;
16
:
526
.
10.
Meng
S
,
Tripathy
D
,
Shete
S
,
Ashfaq
R
,
Haley
B
,
Perkins
S
,
.
HER-2 gene amplification can be acquired as breast cancer progresses
.
Proc Natl Acad Sci U S A
.
2004 Jun 22
;
101
(
25
):
9393
8
.
11.
Jacot
W
,
Cottu
P
,
Berger
F
,
Dubot
C
,
Venat-Bouvet
L
,
Lortholary
A
,
.
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast cancer research
.
Breast Cancer Res
.
2019 Nov 14
;
21
(
1
):
121
.
12.
Fehm
T
,
Mueller
V
,
Banys-Paluchowski
M
,
Fasching
PA
,
Friedl
TWP
,
Hartkopf
A
,
.
Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells – results from the randomized phase III DETECT III trial
.
San Antonio Breast Cancer Symposium; 2020 Dec 8–11; virtual, abstract PD3-12
.
2021
.
13.
Vona
G
,
Sabile
A
,
Louha
M
,
Sitruk
V
,
Romana
S
,
Schütze
K
,
.
Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells
.
Am J Pathol
.
2000 Jan
;
156
(
1
):
57
63
.
14.
Farace
F
,
Massard
C
,
Vimond
N
,
Drusch
F
,
Jacques
N
,
Billiot
F
,
.
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
.
Br J Cancer
.
2011 Sep 6
;
105
(
6
):
847
53
.
15.
Fehm
T
,
Müller
V
,
Aktas
B
,
Janni
W
,
Schneeweiss
A
,
Stickeler
E
,
.
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
.
Breast Cancer Res Treat
.
2010 Nov
;
124
(
2
):
403
12
.
16.
Tang
Y
,
Shi
J
,
Li
S
,
Wang
L
,
Cayre
YE
,
Chen
Y
.
Microfluidic device with integrated microfilter of conical-shaped holes for high efficiency and high purity capture of circulating tumor cells
.
Sci Rep
.
2014 Aug 13
;
4
:
6052
.
17.
Yan
WT
,
Cui
X
,
Chen
Q
,
Li
YF
,
Cui
YH
,
Wang
Y
,
.
Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis
.
Sci Rep
.
2017 Mar 24
;
7
:
43464
.
18.
Ignatiadis
M
,
Rothé
F
,
Chaboteaux
C
,
Durbecq
V
,
Rouas
G
,
Criscitiello
C
,
.
HER2-positive circulating tumor cells in breast cancer
.
PLoS One
.
2011 Jan 10
;
6
(
1
):
e15624
.
You do not currently have access to this content.